Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world
Americas+1 212 318 2000
EMEA+44 20 7330 7500
Asia Pacific+65 6212 1000
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world
Americas+1 212 318 2000
EMEA+44 20 7330 7500
Asia Pacific+65 6212 1000
Bayer’s crop science division saw higher demand and prices for corn seeds.
Bayer AG benefited from surprisingly strong demand for its aging blockbuster eye and blood-thinning medicines in the second quarter, helping the German company raise its forecast for the year.
Sales of the eye treatment Eylea came in at €862 million ($998 million) for the period, exceeding analyst estimates, while blood-thinner Xarelto added another €650 million despite facing new generic competition, according to a statement Wednesday that offered a fuller picture of the company’s performance than last week’s initial announcementBloomberg Terminal.